Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;54(9):e13102.
doi: 10.1111/cpr.13102. Epub 2021 Jul 26.

Current research progress in targeted anti-angiogenesis therapy for osteosarcoma

Yun Liu  1   2   3 , Nenggan Huang  4 , Shijie Liao  1   2   3 , Emel Rothzerg  3   5 , Felix Yao  3 , Yihe Li  3 , David Wood  3 , Jiake Xu  3
Affiliations
Review

Current research progress in targeted anti-angiogenesis therapy for osteosarcoma

Yun Liu et al. Cell Prolif. 2021 Sep.

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumour with a peak in incidence during adolescence. Delayed patient presentation and diagnosis is common with approximately 15% of OS patients presenting with metastatic disease at initial diagnosis. With the introduction of neoadjuvant chemotherapy in the 1970s, disease prognosis improved from 17% to 60%-70% 5-year survival, but outcomes have not significantly improved since then. Novel and innovative therapeutic strategies are urgently needed as an adjunct to conventional treatment modalities to improve outcomes for OS patients. Angiogenesis is crucial for tumour growth, metastasis and invasion, and its prevention will ultimately inhibit tumour growth and metastasis. Dysregulation of angiogenesis in bone microenvironment involving osteoblasts and osteoclasts might contribute to OS development. This review summarizes existing knowledge regarding pre-clinical and developmental research of targeted anti-angiogenic therapy for OS with the aim of highlighting the limitations associated with this application. Targeted anti-angiogenic therapies include monoclonal antibody to VEGF (bevacizumab), tyrosine kinase inhibitors (Sorafenib, Apatinib, Pazopanib and Regorafenib) and human recombinant endostatin (Endostar). However, considering the safety and efficacy of these targeted anti-angiogenesis therapies in clinical trials cannot be guaranteed at this point, further research is needed to completely understand and characterize targeted anti-angiogenesis therapy in OS.

Keywords: VEGF; angiogenesis; anti-angiogenesis; osteosarcoma; sarcoma; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

All authors declare that they have no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Mechanistic insights into the OS targeted anti‐angiogenesis therapy
See this image and copyright information in PMC

References

    1. Moore DD, Luu HH. Osteosarcoma. Cancer Treat Res. 2014;162:65‐92. - PubMed
    1. Friebele JC, Peck J, Pan X, Abdel‐Rasoul M, Mayerson JL. Osteosarcoma: a meta‐analysis and review of the literature. Am J Orthop (Belle Mead NJ). 2015;44(12):547‐553. - PubMed
    1. Kempf‐Bielack B, Bielack SS, Jürgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005;23(3):559‐568. - PubMed
    1. Takeoka H, Yamada K, Naito Y, et al. Phase II trial of carboplatin and pemetrexed plus bevacizumab with maintenance bevacizumab as a first‐line treatment for advanced non‐squamous non‐small cell lung cancer in elderly patients. Anticancer Res. 2018;38(6):3779‐3784. - PubMed
    1. Kantarjian HM, Hughes TP, Larson RA, et al. Correction to: Long‐term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10‐year analysis. Leukemia. 2021;35(2):440‐453. - PMC - PubMed